Biovail Agrees To Cardizem LA Guilty Plea
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal charges say 2003 program gave docs $1,000 to write scrips.
You may also be interested in...
Biovail’s Aplenzin Wins FDA Go-ahead
Firm chalks up good news on antidepressant after plenty of bad.
Biovail Settles For $10 Million On SEC Fraud Charges
Four executives still accused of overstating earnings to deceive investors.
Biovail’s Cardizem LA Marketing Under State Scrutiny
The Massachusetts Attorney General’s office is pursuing a grand jury investigation of Biovail’s program to get physicians to prescribe its long-acting antihypertensive Cardizem LA.